Medical devices, healthcare technology and the business of care
510(k) clearance · K261027

NOVEOS Specific IgE (sIgE); Capture Reagent F014, Soybean (Glycine max); Capture Reagent F017, Hazelnut (Corylus avellana); Capture Reagent F352, Ara h 8 PR-10, Peanut; Capture Reagent F423, Ara h 2, Peanut; Capture Reagent F447, Ara h 6, Peanut

Hycor Biomedical · Decision date Jul 24, 2026

FDA DECISIONK261027

What did the FDA decide?

FDA records K261027 as a 510(k) premarket notification, with a decision dated Jul 24, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Immunology
Decision date
Jul 24, 2026

FDA source record

Regulatory record facts

Identifier
K261027
Regulatory pathway
510(k) premarket notification
Product code
DHB
Decision code
SESE
Decision date
Jul 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Test, Radioallergosorbent (Rast) Immunological.

Product code
DHB
FDA device class
2

FDA decision timeline

  1. K261027 received

    Application receipt date recorded by FDA.

  2. K261027 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DHB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Hycor Biomedical

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Garden Grove, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records